Various preclinical studies highlighted the effects of CUR on NF-kB, STAT3, COX2, and CXCL-1 (chemokine [C-X-C motif] ligand 1) activity, leading to reduced inflammation and eventually also impacting tumor progression. This evidence concerns the gene PTGS2 and neoplasm.